BMS to appeal NICE 'no' on Orencia in RA
This article was originally published in Scrip
Executive Summary
In line with its earlier decision, NICE, the health technology institute for England and Wales, has not recommended the use of Bristol-Myers Squibb's abatacept (Orencia), as a second-line treatment for people with rheumatoid arthritis in its final draft guidance. The company told Scrip that it plans to appeal the decision.